Related Experiment Video
Updated: Jun 4, 2025
Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for
Muneera AlTaweel1,2, Abdulmohsen Almusaad3,2, Gousay Alkhazmari4,5
1Ministry of National Guard Health Affairs (Saudi Arabia), Saudi Arabia.
Insights
COVID-19 significantly impacts the cardiovascular system, causing acute and long-term complications. This review details the mechanisms and genomic factors involved, identifying potential drug targets for cardiovascular disease (CVD) in COVID-19 patients.
Area of Science:
- Cardiology
- Virology
- Genomics
Background:
- COVID-19, initially seen as a respiratory illness, profoundly affects the cardiovascular system.
- Cardiovascular complications of COVID-19 contribute to high mortality and morbidity, impacting long-term quality of life.
- The underlying clinical, cellular, and molecular mechanisms of COVID-19-associated cardiovascular disease (CVD) remain poorly understood.
Purpose of the Study:
- To investigate clinical factors and cellular/molecular mechanisms of acute cardiovascular complications in COVID-19.
- To assess the long-term cardiovascular consequences and sequelae in COVID-19 survivors.
- To identify potential strategies for diagnosis, risk stratification, prevention, and management of cardiovascular issues in COVID-19 patients.
Main Methods:
- Comprehensive review of existing literature on COVID-19 and cardiovascular complications.
- Analysis of genomic sequencing findings related to COVID-19 and cardiovascular disease.
- Examination of cellular and molecular biological pathways involved in COVID-19's cardiovascular impact.
Main Results:
- The relationship between COVID-19 and cardiovascular risk is complex and multifaceted.
- COVID-19 survivors may experience persistent long-term cardiovascular effects.
- Genomic alterations, microRNAs, and novel proteins are implicated in COVID-19-related CVD.
Conclusions:
- Understanding the pathophysiology of COVID-19's cardiovascular effects is crucial for patient outcomes.
- Identifying novel drug targets through genomic and molecular analysis can aid in treating COVID-19-related cardiovascular complications.
- This review provides insights for improved clinical management and prevention strategies for cardiovascular sequelae post-COVID-19.
Abstract:
COVID-19 was initially identified as a respiratory system disorder, but it has been reported to interact with and influence the cardiovascular system, in addition to many other body systems. Although COVID-19-associated cardiovascular (CV) complications are common, resulting in high acute phase mortality and a large number of morbidities in the chronic phase, thus severely impacting patients' quality of life and health outcomes, yet clinical, cellular, and molecular biological factors underlying the pathophysiology of cardiovascular complications associated with COVID-19 are poorly understood. This review investigates putative underlying clinical factors as well as cellular and molecular biological mechanisms by which COVID-19 leads to acute CV complications, including state-of-the-art genomic sequencing-based findings, and assessing the long-term CV consequences of COVID-19, aiming to shed light on developing strategies for differential diagnosis, risk prognostic stratification, prevention, and clinical management of CV sequels in COVID-19 patients. We found that the relationship between COVID-19 and CV risk is complex and multifaceted. Intriguingly, in addition to acute COVID-19 detertriuos effects, COVID-19 survivors may experience long-term CV effects as well that may have long-lasting clinical consequences. Here in this article, we provide a detailed account of a large number of genomic alterations, microRNAs, and novel viral as well as host proteins in CVDs associated with COVID-19, which has helped identify some novel drug targets to treat COVID-19-related cardiovascular complications.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:23Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:29Pathophysiology of Cardiac Performance